Amphastar Signs New Executive Employment Agreements With Liawatidewi and Zhou

Reuters03-07
Amphastar Signs New Executive Employment Agreements With Liawatidewi and Zhou

Amphastar Pharmaceuticals Inc. entered into new one-year executive employment agreements effective March 3, 2026 with Jacob Liawatidewi and Rong Zhou. Liawatidewi’s base salary is set at $525,800 with a target annual bonus of 55% of salary, while Zhou’s base salary is $590,000 with a 53% target bonus. The agreements provide severance on a qualifying termination of two times salary plus the average of the prior two years’ bonuses, up to 12 months of health premium payments, and full acceleration of unvested equity awards, with enhanced benefits if the termination occurs within a year after a change in control.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001297184-26-000015), on March 06, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment